Lipid Nanoparticle Formulation Aggregation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of short interfering RNA (siRNA) is hindered by rapid enzymatic degradation and poor cellular uptake and bioavailability, leading to instability and aggregation issues in lipid nanoparticle (LNP) formulations, which existing technologies have not adequately addressed.
Innovation Solution
A pharmaceutical formulation comprising lipid nanoparticles in a non-ionic or de-ionized medium, free of negative counter-ions, with a pH below the pKa of the cationic lipid, which inhibits aggregation and maintains stability even after mechanical disturbances, such as vortexing, by ensuring a unimodal particle size distribution and reduced aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If PEGylated lipids are included to inhibit aggregation, then aggregation is reduced, but intracellular delivery and trafficking are affected
Solution Approach 1:
The patent removes PEGylated lipids from the LNP formulation entirely, replacing them with alternative aggregation-inhibiting mechanisms that do not interfere with intracellular delivery. This extraction of the problematic component resolves the contradiction by eliminating the harmful effect while maintaining the beneficial aggregation inhibition through different means.
Solution Approach 2:
The patent changes the formulation parameters by using specific lipid compositions and ratios, adjusting pH levels, and optimizing the charge density of cationic lipids to achieve aggregation inhibition without PEG. These parameter changes allow the system to maintain stability while avoiding the intracellular delivery issues caused by PEGylation.
2Stability of the object's composition
If shaking is performed to break up aggregates, then aggregation is reduced, but aggregation may not be sufficiently broken and there is risk of non-compliance
Solution Approach 1:
The patent incorporates aggregation-inhibiting components into the formulation during manufacturing, so that aggregates are prevented from forming in the first place rather than requiring post-formulation shaking to break them up. This preliminary action ensures consistent performance regardless of whether the patient shakes the formulation.
Solution Approach 2:
The formulation contains self-stabilizing components that actively prevent aggregation over time without requiring external intervention. The lipid composition and formulation conditions create a self-regulating system that maintains stability automatically, eliminating the need for patient compliance with shaking instructions.
3Productivity
If cationic lipids are used to enhance cellular uptake, then delivery efficiency is improved, but aggregation increases due to electrostatic interactions
Solution Approach 1:
The patent uses a mixture of cationic lipids with different properties and incorporates anionic or neutral lipids in specific ratios. This creates local charge balance within the nanoparticle structure, allowing the cationic components to maintain cellular uptake efficiency while their charge interactions are locally neutralized to prevent aggregation.
Solution Approach 2:
The patent creates a composite lipid formulation combining cationic, anionic, and neutral lipids in optimized ratios. This composite structure allows the cationic lipids to provide cellular uptake enhancement while the other lipid types counterbalance their charge and prevent aggregation, achieving both functions simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves enhanced stability and reduced aggregation of lipid nanoparticles, maintaining particle size distribution and encapsulation efficiency, thereby improving the delivery and bioavailability of siRNA by minimizing enzymatic degradation and aggregation.
Implementation Method 1
Each nanoparticle comprises a cationic lipid and an active pharmaceutical ingredient (such as a nucleic acid)
Implementation Method 2
aggregation of lipid nanoparticles, especially those for delivering nucleic acids, can be inhibited with a formulation that is substantially free of negative counter-ions (i.e., anions). The medium for the formulation preferably is non-ionic or de-ionized
Data Source
AI summary
The present invention relates to stable lipid nanoparticle pharmaceutical formulations which are substantially free of large aggregates (e.g., aggregates greater than 1 μm in size) and include a substantially non-ionic medium.